About this document
Targeting UBE2N in MDS and AML by vidhisphotos is a document available to read on EtoBox.
This study investigates the therapeutic potential of inhibiting UBE2N in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), revealing that UBE2N inhibition reduces the viability of MDS/AML cells while sparing normal hematopoietic stem and progenitor cells. The findings indicate that UBE2N inhibition leads to TRAF6 degradation and alters ubiquitination patterns, which may enhance the efficacy of Lenalidomide in treating various MDS/AML subtypes. Overall, UBE2N emerges as a promising target for
- Author
- vidhisphotos
- Language
- EN